Categories: News

Delota Corp. Announces Grant of Options And RSUs

Vaughan, Ontario–(Newsfile Corp. – July 11, 2023) – Delota Corp. (CSE: LOTA) (“Delota” or the “Company“) an established Canadian vape and cannabis retailer, is pleased to announce the grant of stock options (each an “Option“) and restricted share units (each an “RSU“) pursuant to the Company’s omnibus plan (the “Plan“).

The Company has granted an aggregate of 1,710,000 Options and an aggregate of 640,000 RSUs to certain directors, officers, employees, and consultants of the Company. Each Option is exercisable at a price of $0.11 per common share, expires four years from the date of grant and vests immediately. Each Option is exercisable to purchase one common share in the capital of the Company. Each RSU granted vests immediately. All of the Options and RSUs (and any common shares issuable upon exercise thereof) will be subject to a four month and one day hold period pursuant to the polices of the Canadian Securities Exchange and applicable securities laws.

About Delota Corp.

Delota is an established vape and cannabis retailer that curates and sells vape and nicotine-related products, other smoking cessation products, cannabis products, and accessories where regulations permit. The Company currently operates 28 brick-and-mortar specialty vape stores in Ontario under the 180 Smoke Vape Store banner name, a leading Canada-wide specialty vape e-commerce platform (www.180smoke.ca), and five licensed dispensaries under the Offside Cannabis banner name in Ontario.

For further information, please contact:

Delota Corp.

Cameron Wickham
Executive Vice Chair and CEO
T: (905) 330-1602
E: info@delota.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/173066

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

35 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

35 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago